Filing Details
- Accession Number:
- 0001415889-24-010604
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-04-09 18:00:18
- Reporting Period:
- 2024-04-05
- Accepted Time:
- 2024-04-09 18:00:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1131146 | Stephen Davis | C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130 | Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-04-05 | 17,333 | $0.00 | 136,175 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-04-05 | 34,666 | $0.00 | 170,841 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-04-08 | 8,858 | $17.87 | 161,983 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-04-08 | 17,716 | $17.87 | 144,267 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2024-04-05 | 17,333 | $0.00 | 17,333 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2024-04-05 | 34,666 | $0.00 | 34,666 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 34,667 | No | 4 | M | Direct | ||
| 138,666 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.775 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.77 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The restricted stock units vest in four equal annual installments beginning April 5, 2023.
- Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from April 5, 2022 (the "grant date"); 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
Billionaire Hedge Funds
